Could an antidepressant slow COVID-19 progression?
RI-MUHC researchers launch a clinical trial of fluvoxamine, a drug that has already proven efficient in reducing lung injury in animal studies and...
Clinical Innovation Platform at the RI-MUHC announces first member company
Health tech accelerator welcomes AltPAP Innovation to its new state-of-the-art facility
Could a different testing strategy reduce healthcare workers’ isolation after unprotected exposure to a confirmed case of COVID-19?
RI-MUHC study suggests appropriate...
Haply wins the CODE LiFE Ventilator Challenge
What’s next? “Gather the resources to bring the Haply device to millions around the world,” says Reza Farivar
Researchers identify the origin of a deadly brain cancer
Finding could lead to potential therapies
The RI-MUHC leads new clinical trial of COVID-19 treatment for hospitalized patients
Phase 2 study tests LAU-7b, a Canadian drug with dual antiviral and inflammation-controlling effects
RI-MUHC veterinarians engage in global effort to understand SARS-Cov-2
ARD platform members take centre stage at the 2020 Quebec Veterinary Congress
RI-MUHC researcher Nitika Pant Pai advocates improved access to HIV self-testing for Canadians
Canada approves HIV self-testing kit ahead of World AIDS Day 2020
Driving Personalized Medicine: The 2020 RI-MUHC Annual Report is online!
An invitation from Dr. Miguel Burnier Jr.
RI-MUHC team identifies new gene associated with risk of cardiovascular diseases
New study analyses millions of genetic variants in almost 300,000 individuals